|
Post by bernstein on Jun 27, 2017 14:11:46 GMT
|
|
|
Post by bernstein on Jun 29, 2017 15:47:30 GMT
|
|
|
Post by hansgruber on Jun 29, 2017 18:55:55 GMT
Started a position. I like the science on this one. Neat stuff.
|
|
|
Post by CM kipper007 on Jun 29, 2017 21:11:08 GMT
INTELGENX FILES FINAL SHORT FORM PROSPECTUS IN CONNECTION WITH OFFERING OF CONVERTIBLE UNSECURED DEBENTURESJune 29, 2017 SAINT LAURENT, QUEBEC -- (Marketwired) -- 06/29/17 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Corporation" or "IntelGenx") is pleased to announce that it has filed a final short form prospectus (the "Prospectus") in connection with an offering (the "Offering") of a minimum of Cdn$5,000,000 and a maximum of Cdn$10,000,000 aggregate principal amount of 8% convertible unsecured subordinated debentures due June 30, 2020 (the "Debentures"). The Corporation has also filed an amended registration statement on Form S-1 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC") to register the Debentures and the shares of common stock underlying the Debentures. The Offering is being conducted on a commercially reasonable best efforts basis by a syndicate of agents led by Desjardins Capital Markets and including Laurentian Bank Securities Inc. and Echelon Wealth Partners Inc. and is expected to close on or about July 12, 2017. The Debentures will bear interest at an annual rate of 8%, payable semi-annually on the last day of June and December of each year, commencing on December 31, 2017. Each Debenture will be convertible at a conversion price of Cdn$1.35 per common share of the Corporation ("Shares"), being a conversion rate of approximately 740 Shares per $1,000 principal amount of Debentures, subject to adjustment in certain events. The net proceeds from the Offering will be used for capital expansion, clinical studies, product development and general working capital requirements. The TSX Venture Exchange ("TSXV") has conditionally approved the listing of the Debentures and the Shares issuable on the conversion of the Debentures or pursuant to other terms of the Debentures. A copy of the Prospectus is available under the Corporation's profile at www.sedar.com and a copy of the Registration Statement can be obtained from the SEC's website at www.sec.gov. The Offering is subject to certain customary conditions including, but not limited to, the receipt of all necessary approvals, including the SEC declaring the Registration Statement effective. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.
|
|
|
Post by CM kipper007 on Jul 12, 2017 18:33:50 GMT
INTELGENX COMPLETES CDN$6.8 MILLION CONVERTIBLE DEBENTURE OFFERINGJuly 12, 2017 SAINT LAURENT, QUEBEC -- (Marketwired) -- 07/12/17 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Corporation" or "IntelGenx") is pleased to announce that it has closed its previously announced prospectus offering (the "Offering") of convertible unsecured subordinated debentures of the Corporation (the "Debentures") for gross aggregate proceeds of CDN$6,838,000. Pursuant to the Offering, the Corporation issued an aggregate principal amount of CDN$6,838,000 of Debentures at a price of CDN$1,000 per Debenture. The Debentures will mature on June 30, 2020 and bear interest at annual rate of 8% payable semi-annually on the last day of June and December of each year, commencing on December 31, 2017. The Debentures will be convertible at the option of the holders at any time prior to the close of business on the earlier of June 30, 2020 and the business day immediately preceding the date specified by the Corporation for redemption of Debentures. The conversion price will be CDN$1.35 (the "Conversion Price") per common share of the Corporation ("Share"), being a conversion rate of approximately 740 Shares per CDN$1,000 principal amount of Debentures, subject to adjustment in certain events. The Debentures are not redeemable prior to June 30, 2018. On or after June 30, 2018, but prior to June 30, 2019, the Debentures may be redeemed at the Corporation's sole option, in whole or in part, from time to time on required prior notice at a redemption price equal to the principal amount of the Debentures, provided that the current market price on the date on which such notice of redemption is given is not less than 125% of the Conversion Price. On or after June 30, 2019 and prior to June 30, 2020, the Debentures may be redeemed at the Corporation's sole option, in whole or in part, from time to time on required prior notice, at a redemption price equal to the principal amount of the Debentures, irrespective of the current market price. In addition thereto, at the time of redemption, the Corporation will pay to the holder accrued and unpaid interest up to but not including the date of redemption. The Debentures were distributed under a short form prospectus dated June 28, 2017 filed by the Corporation in connection with the Offering and available on SEDAR at www.sedar.com. The Offering was conducted, on a best efforts basis, by a syndicate of agents led by Desjardins Capital Markets and including Laurentian Bank Securities Inc. and Echelon Wealth Partners Inc. (collectively, the "Agents"). In consideration for the services rendered by the Agents, the Corporation has paid the Agents an agency fee of CDN$405,280. The Debentures will commence trading on the TSX Venture Exchange today under the stock symbol IGX.DB. The Corporation intends to use the aggregate net proceeds from the Offering for capital expansion, clinical studies, product development and general working capital requirements. The Debentures and the common shares issuable upon conversion, redemption or maturity of the Debentures have been registered with the United States Securities and Exchange Commission pursuant to a Form S-1 Registration Statement that was declared effective on July 11, 2017 (the "Registration Statement"). Certain insiders of the Corporation participated in the Offering and purchased an aggregate of $120,000 principal amount of Debentures. Participation of insiders of the Corporation in the Offering constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"), but is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of securities being issued to insiders nor the consideration being paid by insiders exceeds 25% of the Corporation's market capitalization. None of the Corporation's directors has expressed any contrary views or disagreements with respect to the foregoing. The Corporation did not file a material change report 21 days prior to the closing of the Offering as the details of the participation of the insiders of the Corporation had not been confirmed at that time.
|
|
|
Post by CM kipper007 on Jul 13, 2017 0:41:25 GMT
INTELGENX PRESENTS AT BIT'S 7TH ANNUAL INTERNATIONAL SYMPOSIUM OF DRUG DELIVERY SYSTEMSJuly 12, 2017 SAINT LAURENT, QUEBEC -- (Marketwired) -- 07/12/17 -- IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") announced that Dr. Rodolphe Obeid, its Director of Research and Development, Process Development and Manufacturing Scale-Up, discussed the Company's oral films based on its proprietary VersaFilm™ technology platform during a presentation today at BIT's 7th Annual Symposium of Drug Delivery Systems being held in Prague, Czech Republic. Entitled "Oral Film Technology Evolution, Challenges and Therapeutic Benefits," Dr. Obeid's presentation reviewed the Company's development of VersaFilm™ and the technology platform's potential to enhance active pharmaceutical ingredient bioavailability, accelerate onset of action, reduce side effects and ease administration, thereby improving patient's compliance and satisfaction. Dr. Obeid is an expert in drug delivery systems and polymeric assemblies. In his current role, Dr. Obeid is responsible for overseeing all of IntelGenx' product development activities. Based on IntelGenx' current pipeline, there are eight different film projects in various development stages, five of which are under co-development with a commercial partner. Here, Dr. Obeid is in charge of overseeing the technology transfer, as well as the process development and manufacturing scale-up of all internal and external pharmaceutical film projects. Prior to joining IntelGenx, Dr. Obeid was a postdoctoral industrial R&D Fellow at the Faculty of Veterinary Medicine of University of Montreal, working on vaccine encapsulation using biodegradable microspheres. Before that, he was a National Institutes of Health Postdoctoral Scholar at the University of Alabama in collaboration with the Massachusetts Institute of Technology, focusing on the development of novel poly-based polymers for surface modification of biomedical implants as a part of the Boston Retinal Implant Project. Dr. Obeid holds a Ph.D in polymer chemistry from the University of Montreal, Canada and two Masters in polymer science and chemical engineering from the University of Strasbourg, France. Dr. Obeid is the co-inventor of multiple pending patent applications, and has published numerous scientific articles on recognized international journals and conferences. "Our talented R&D team continues to break new ground in the development of oral film technology, and we were excited to have this opportunity to present their progress to an international audience of scientists from industry and academia, as well as leaders from healthcare providers and policy makers," Horst G. Zerbe, CEO of IntelGenx.
|
|
|
Post by bernstein on Nov 3, 2017 15:51:05 GMT
Great time to load up nowafter they resubmit the NDA for Rizaport early this week .GL RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines..November 1, 2017 finance.yahoo.com/news/redhill-biopharma-intelgenx-submit-drug-110100087.htmlMarket Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive . Intelgenx (IGXT) Markt-Cap $48 Million Cash 8.1 Million Price: $0.73 FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million) NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million) Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug) Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired Presentation s2.q4cdn.com/790425727/files/doc_presentations/2017/09/INTELGENX-Presentation-September-2017_final.pdfinvestorintel.com/sectors/biotech/biotech-intel/intelgenx-thin-film-market/
|
|
|
Post by hansgruber on Sept 21, 2018 11:17:28 GMT
Well this thing just doubled yesterday on news of a deal with tilray marijuana. I still had a relatively small.position. anyone else following this one still?
|
|
|
Post by JHam on Sept 21, 2018 11:54:58 GMT
Well this thing just doubled yesterday on news of a deal with tilray marijuana. I still had a relatively small.position. anyone else following this one still? I don’t but congrats!
|
|
|
Post by selluwud on Sept 21, 2018 13:39:44 GMT
Well this thing just doubled yesterday on news of a deal with tilray marijuana. I still had a relatively small.position. anyone else following this one still? I don’t but congrats! I made a little money here earlier in the year but bailed out happy to be ahead after watching it stay below my cost most of the time. Congrats to all that benefited.
|
|
|
Post by CM kipper007 on Apr 24, 2019 19:47:53 GMT
Anyone still following this?
|
|
|
Post by JHam on Apr 25, 2019 15:12:21 GMT
Anyone still following this? I'm not. What did I miss?
|
|
|
Post by magnus123 on Apr 25, 2019 15:30:29 GMT
Anyone still following this? I'm not. What did I miss? I followed IGXT for a long time, but never invested. Their Management is just completely incompetent. They are trying to get the approval for Rizaport now for appr. 5 Years and they dont get it...just stupid:D
|
|